Decera Clinical Education Pharmacy Practice Podcast

Our Experiences With the Latest Treatment Options in Ovarian Cancer: The Pharmacist Perspective

Episode Summary

Experts discuss their experiences with providing patient education on PARP inhibitors and mirvetuximab soravtansine and a potentially emerging treatment modality in advanced ovarian cancer.

Episode Notes

In this episode, Sarah Hayward, PharmD, BCOP, and Amy Ly Indorf, PharmD, BCOP, discuss their experiences providing care for patients with advanced ovarian cancer, with topics including:

• PARP inhibitors as frontline maintenance therapy
• Patient education and counseling on PARP inhibitors
• Helping patients access newer therapies
• Experiences with mirvetuximab soravtansine
• Patient education and counseling on mirvetuximab soravtansine
• Treatment modalities on the horizon 

Presenters:

Sarah Hayward, PharmD, BCOP
Clinical Pharmacy Specialist,
Gynecologic Oncology
Stephenson Cancer Center at
OU Health
Oklahoma City, Oklahoma

Amy Ly Indorf, PharmD, BCOP
Clinical Assistant Professor
University of Washington 
School of Pharmacy
Clinical Oncology Pharmacist
UW Medicine
Fred Hutchinson Cancer Center
Seattle, Washington

Supported by educational grants from GSK and Novocure, Inc.

Link to full program:
https://bit.ly/44fUiOU